A carregar...
Development and dynamics of robust T-cell responses to CML under imatinib treatment
Novel molecular targeted therapies, such as imatinib for chronic myelogenous leukemia (CML), represent the first agents that inhibit cancer cells more than other dividing cells, such as immune cells. We hypothesize that imatinib may create a window in which the immune response is partially restored...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2008
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2396727/ https://ncbi.nlm.nih.gov/pubmed/18326818 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2007-12-128397 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|